Systemic therapy against unresectable hepatocellular carcinoma

Systemic therapy against unresectable hepatocellular carcinoma - Systemic therapy against u-HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043219

Enrollment

1000

Registered

2021-02-01

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable liver cancer who received systemic drug treatment

Exclusion criteria

Exclusion criteria: Patients who disagree with data use

Design outcomes

Primary

Measure	Time frame
Overall survival after introducing initial systemic treatment	—

Secondary

Measure	Time frame
Anti-tumor responses of systemic treatments (RECIT/ mRECIST), Progression free survival and time to progression of each systemic treatment, adverse events of each systemic treatment, relative changes of hepatic reserve function, nutritional status, tumor markers, physical conditions (muscle volume, muscle strength, body weight), adverse event	—

Countries

Japan

Contacts

Public ContactAtsushi Hiraoka

Ehime Prefectural Central Hospital Gastroenterology Center

hirage@m.ehime-u.ac.jp81899471111

Outcome results